D-1871-2019 Class II Terminated

Recalled by Aurolife Pharma, LLC — Dayton, NJ

FDA drug recall D-1871-2019 was initiated by Aurolife Pharma, LLC on Aug 23, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Aug 16, 2022). Affected quantity: 6104 bottles.

Recall Details

Product Type
Drugs
Report Date
Sep 25, 2019
Initiation Date
Aug 23, 2019
Termination Date
Aug 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6104 bottles

Product Description

Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK; Manufactured for: Aurohealth LLC., 2572 Brunswick Pike, Lawrenceville, NJ 08648; Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810.

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution Pattern

Nationwide in the USA

Code Information

Lot #s:067180011A, 067180012A, Exp 04/21, 06718027B1, Exp 09/21

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1871-2019
openFDA file date
Nov 3, 2026
Loaded by RegDataLab
Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1871-2019. Report a data issue: hello@regdatalab.com.